EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Flerie AB (publ) (FLERIE) fair value: what the stock is really worth

As of Oct 13, 2026: fair value of Flerie AB (publ) SEK 6.93, price SEK 15.80, upside -56.2%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0022447348

FA Thin data Oct 2, 2026

Flerie AB (publ)

FLERIE · ST

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 56% below what the stock costs today.

Mixed Growth (revenue 5y +202.1 %/yr in SEK)
Fair value kr 6.93 · Strongly overvalued (−56.2%)
Quality 28/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 14/100 · thin data
Thin data
⚠ Dilution
Watch Flerie AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 48.83 kr 0.0050 Fair Value kr 6.93 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range kr 0.0050 – kr 48.83 · fair‑value band kr 4.57 – kr 8.66 · the kr 15.80 price screens above the kr 6.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Flerie AB (publ) in your weekly email

Every Wednesday you see whether Flerie AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel.

Show more

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.

Stock analysis

Flerie AB (publ) (FLERIE) currently trades at kr 15.80, while our model-based Fair Value estimate is kr 6.93, 56.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: kr 4.57 (bear) to kr 8.66 (bull), the price of kr 15.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Flerie AB (publ) reported revenue of 8.8M SEK in FY2025 versus 35.0K SEK in FY2020, a compound +202.1%/yr. Reported net income was −757M SEK in FY2025.

Key figures

Market cap 1.4B SEK (≈ $144M) · EPS (TTM) kr −9.48 · Return on equity −22.2% · Return on assets (EBIT) −26.1% · Operating margin −746% · Revenue (TTM) −5.6M SEK · Revenue growth (YoY) −85.1% · EPS growth (YoY) +39.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −56%, FLERIE screens richer than that median.

Fair Value models

Bear kr 4.57 Fair Value kr 6.93 Bull kr 8.66
Price kr 15.80 · Upside -56.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 19.48 kr 26.10 kr 38.95 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 19.48 kr 26.10 kr 38.95 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

Of which business quality 28 · Market factors (momentum, volatility) 28

Profitability 0
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 82
Calm price path (market factor)
Momentum 7
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+202.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−164,940.0% (2020) → −8,887.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FLERIE screens overvalued: fair value 56% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Flerie AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −56.2% · Below median
Profitability
Return on assets −0.7% · Above median
Growth and dividend
Revenue growth −85.1% · Bottom 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs FLERIE
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs FLERIE
argenx SE ARGX $825.03 $907.53 +10% vs FLERIE
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs FLERIE
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs FLERIE
CSL Limited CSL A$181.46 A$179.90 −1% vs FLERIE
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs FLERIE
BeOne Medicines AG ONC $354.47 $280.94 −21% vs FLERIE
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs FLERIE
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs FLERIE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Flerie AB (publ) · Fair Value
kr 6.93 −56%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Flerie AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/FLERIE

Frequently asked questions

Is Flerie AB (publ) (FLERIE) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of kr 6.93 versus a price of kr 15.80, about −56% upside (overvalued).
What is the fair value of FLERIE?
Our model-based fair value for Flerie AB (publ) is kr 6.93 (as of Oct 2, 2026), built from audited fundamentals. The current price: kr 15.80.
What is the quality score of FLERIE?
Flerie AB (publ) has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Flerie AB (publ) (FLERIE)?
Our model-based price target is the fair value of kr 6.93 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario kr 4.57, optimistic scenario kr 8.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Flerie AB (publ) stock forecast for 2026?
Our models put fair value at kr 6.93, about −56% upside versus a price of kr 15.80 (overvalued). Cautious scenario kr 4.57, optimistic scenario kr 8.66. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Flerie AB (publ) (FLERIE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Flerie AB (publ) it is kr 6.93 per share (as of Oct 2, 2026), against a price of kr 15.80. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Flerie AB (publ) stock overvalued or undervalued in 2026?
As of Oct 2, 2026, FLERIE trades above its calculated fair value: price kr 15.80, fair value kr 6.93, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FLERIE?
No. The price is what the market pays today (kr 15.80); the fair value is what the company's own numbers justify (kr 6.93). For Flerie AB (publ) the two are kr 8.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Flerie AB (publ) worth?
The market values Flerie AB (publ) at about 1.4B SEK (market capitalisation, as of Oct 2, 2026). Per share that is kr 15.80; our models calculate a fair value of kr 6.93 per share.
What do the bullish and bearish scenarios say about FLERIE?
Our models span a range for Flerie AB (publ): cautious scenario kr 4.57, base kr 6.93, optimistic kr 8.66 per share (as of Oct 2, 2026, price kr 15.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Flerie AB (publ) (FLERIE)?
Balance-sheet figures for Flerie AB (publ) (as of Oct 2, 2026): return on equity −22.2%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is FLERIE from its 52-week high?
Flerie AB (publ) trades at kr 15.80, about 56% below its 52-week high of kr 35.70 and 5% above the low of kr 15.10 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 6.93 is for.
Which stocks are comparable to Flerie AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Flerie AB (publ) stock attractive at the current price?
The data as of Oct 2, 2026: price kr 15.80, calculated fair value kr 6.93 (−56%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FLERIE calculated?
We run Flerie AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 6.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Flerie AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Flerie AB (publ) (FLERIE)?
The closing price on Oct 13, 2026 was kr 15.80. Our model-based fair value is kr 6.93, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Flerie AB (publ) right now?
The price sits above even our optimistic bull case (kr 8.66). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 4.57 to kr 8.66) leaves room in how you read the outcome.

Key figures of Flerie AB (publ)

How large is the market capitalisation of Flerie AB (publ) (FLERIE)?
The market capitalisation of Flerie AB (publ) is 1.4B SEK (≈ $144M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Flerie AB (publ) (FLERIE)?
Earnings per share at Flerie AB (publ) are kr −9.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Flerie AB (publ) (FLERIE)?
The return on equity (ROE) of Flerie AB (publ) is −22.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Flerie AB (publ) (FLERIE)?
On an EBIT basis the return on assets of Flerie AB (publ) is −26.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Flerie AB (publ) (FLERIE)?
The operating margin of Flerie AB (publ) is −746% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Flerie AB (publ) (FLERIE) generate?
Flerie AB (publ) generates revenue of −5.6M SEK (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Flerie AB (publ) (FLERIE)?
Revenue at Flerie AB (publ) is growing −85.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Flerie AB (publ) (FLERIE)?
Earnings per share at Flerie AB (publ) are growing +39.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Flerie AB (publ) (FLERIE) generate?
The free cash flow of Flerie AB (publ) is −28.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Flerie AB (publ) (FLERIE) hold?
Flerie AB (publ) holds more cash than debt, 537M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Flerie AB (publ) in the live analysis

One click puts Flerie AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.